This is a phase 1 study of atezolizumab in combination with D2C7-IT, a dual-specific
monoclonal antibody (mAB) with a high affinity for both EGFRwt- and EGFRvIII-expressing
cells, in patients with recurrent World Health Organization (WHO) grade IV malignant glioma
at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
Phase:
Phase 1
Details
Lead Sponsor:
Darell Bigner Darell D. Bigner, MD, PhD
Collaborators:
Genentech, Inc. Istari Oncology, Inc. National Cancer Institute (NCI)